18-Nov-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the companys management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY. Details are as follows: Pi
13-Nov-2025 3:01 PM CST - Business Wire Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its nancial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipat
4-Nov-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Companys Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, November 18, 2025, at 9:30 AM GMT. Management will also host investor one-on-one meetings throughout the conference. The Jeffer
13-Oct-2025 6:30 AM CST - Business Wire Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or
21-Aug-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Companys Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will
14-Aug-2025 3:01 PM CST - Business Wire Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its nancial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for
15-Jul-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Companys Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be
20-May-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in Upcoming Investor Conferences #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced that the Companys Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 5, 2025, in New Yor
13-May-2025 3:05 PM CST - Business Wire Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Subsequent Period Highlights: Tvardi completed its merger with Cara Therapeutics. Tvardi received approxima
18-Nov-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the companys management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY. Details are as follows: Pi
13-Nov-2025 3:01 PM CST - Business Wire Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its nancial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipat
4-Nov-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Companys Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, November 18, 2025, at 9:30 AM GMT. Management will also host investor one-on-one meetings throughout the conference. The Jeffer
13-Oct-2025 6:30 AM CST - Business Wire Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or
21-Aug-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Companys Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will
14-Aug-2025 3:01 PM CST - Business Wire Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its nancial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for
15-Jul-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Companys Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be
20-May-2025 7:00 AM CST - Business Wire Tvardi Therapeutics to Participate in Upcoming Investor Conferences #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced that the Companys Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 5, 2025, in New Yor
13-May-2025 3:05 PM CST - Business Wire Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat brosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Subsequent Period Highlights: Tvardi completed its merger with Cara Therapeutics. Tvardi received approxima
